Dimerix Stock

Dimerix Net Debt

The Net Debt of Dimerix (DXB.AX) as of Jul 20, 2026 is -68.19 M AUD. In the previous year, Net Debt was -21.99 M AUD — a change of 210.05% (lower).

Net Debt

-68.19 MAUD

YoY

210.05%

Last updated:

Net Debt of Dimerix is 2026 -68.19 M AUD. Net Debt of Dimerix was 2025 -21.99 M AUD. It decreases by 210.05% lower compared to the previous year.
Access this data via the Eulerpool API

Dimerix Stock analysis

What does Dimerix do? Dimerix Ltd is an Australian biotechnology company specializing in the development of innovative therapies for various medical needs. Their business model is based on identifying new targets for drug development, often through collaborations with other biotech or pharmaceutical companies. Dimerix focuses on cancer therapy, utilizing their innovative platform technology to identify and test a variety of drug candidates. They also have a pipeline of medications for kidney and lung diseases, as well as inflammation and pain. Dimerix actively seeks partnerships with other companies and research institutions to bring innovative therapies to market. One of their key products, DMX-200, is currently in phase II clinical trials for the treatment of kidney diseases and has shown promising results. Overall, Dimerix is well-positioned to continue bringing successful therapies to market in the future. Dimerix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dimerix stock

Net Debt of Dimerix is -68.19 M AUD in 2026.

Access this data via the Eulerpool API

Balance Sheet — Dimerix

All Key Metrics — Dimerix